BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35190110)

  • 1. Tumor Lysis Syndrome.
    Barbar T; Jaffer Sathick I
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].
    Burghi G; Berrutti D; Manzanares W
    Med Intensiva; 2011 Apr; 35(3):170-8. PubMed ID: 21112673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome: new challenges and recent advances.
    Wilson FP; Berns JS
    Adv Chronic Kidney Dis; 2014 Jan; 21(1):18-26. PubMed ID: 24359983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of pediatric tumor lysis syndrome.
    Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
    Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute renal failure in patients with tumour lysis sindrome].
    Poskurica M; Petrović D; Poskurica M
    Srp Arh Celok Lek; 2016; 144(3-4):232-9. PubMed ID: 27483573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of tumor lysis syndrome.
    Rampello E; Fricia T; Malaguarnera M
    Nat Clin Pract Oncol; 2006 Aug; 3(8):438-47. PubMed ID: 16894389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.
    Matuszkiewicz-Rowinska J; Malyszko J
    Kidney Blood Press Res; 2020; 45(5):645-660. PubMed ID: 32998135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor lysis syndrome.
    Jeha S
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):4-8. PubMed ID: 11694945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
    Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
    Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing tumor lysis syndrome.
    Greguska C
    JAAPA; 2021 Jan; 34(1):10-13. PubMed ID: 33315730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Our experience with tumor lysis syndrome treatment.
    Sirelkhatim A; Sejnova D; Puskacova J; Subova Z; Kaiserova E
    Bratisl Lek Listy; 2008; 109(12):560-3. PubMed ID: 19348378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.